"10.1371_journal.pone.0130072","plos one","2015-06-23T00:00:00Z","Eduardo M Moreira; Henning Gall; Maarten J G Leening; Lies Lahousse; Daan W Loth; Bouwe P Krijthe; Jessica C Kiefte-de Jong; Guy G Brusselle; Albert Hofman; Bruno H Stricker; Hossein A Ghofrani; Oscar H Franco; Janine F Felix","Department of Epidemiology, Erasmus MC, Rotterdam, the Netherlands; School of Medicine, Pontifical Catholic University of Parana, Curitiba, Brazil; Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Giessen, Germany; Department of Cardiology, Erasmus MC, Rotterdam, the Netherlands; Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium; Department of Respiratory Medicine, Amphia Hospital, Breda, the Netherlands; Department of Respiratory Medicine, Erasmus MC, Rotterdam, the Netherlands; Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands; Inspectorate for Health Care, The Hague, the Netherlands","Conceived and designed the experiments: EMM HG AH HAG OHF JFF. Performed the experiments: EMM HG LL DWL BPK. Analyzed the data: EMM HG MJGL JCKdJ JFF. Wrote the paper: EMM HG MJGL LL DWL BPK JCKdJ GGB AH BHS HAG OHF JFF. Interpretation of the data: EMM HG MJGL LL DWL BPK JCKdJ GGB AH BHS HAG OHF JFF.","The authors have the following interests: JCK-dJ and OHF work in ErasmusAGE, a center for aging research across the life course funded by Nestl√© Nutrition (Nestec Ltd.), Metagenics Inc. and AXA. H.G. has received support and/or honoraria from Actelion, AstraZeneca, Bayer, GlaxoSmithKline, Janssen Cilag, Lilly, Pfizer, and United Therapeutics/OMT. H.A.G. reports personal fees from Actelion, Bayer, Ergonex, Gilead, GSK, Merck, Novartis, Pfizer and grants from Actelion, Bayer, Ergonex, Pfizer outside the submitted work. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2015","06","Eduardo M Moreira","EMM",13,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
